Previous research has implicated the serotonin-2B (5-HT2B) receptor as a possible contributor to the antidepressant-like response. Aripiprazole has been successfully used in combination with selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant depression and it, among all receptors, exhibits the highest affinity for the 5-HT2B receptor. However, the potential contribution of such an antagonistic action on 5-HT2B receptors in the context of adjunct therapy is not known. In vivo electrophysiological recordings of ventral tegmental area (VTA) dopamine (DA) neurons, dorsal raphe nucleus (DRN) 5-HT neurons and pyramidal neurons in the medial prefrontal cortex (mPFC), and the hippocampus were conducted in anaesthetized Sprague-Dawley rats after the administration of 5-HT2B receptor ligands alone or in combination with the SSRI escitalopram. An escitalopram-induced decrease in DA, but not 5-HT firing activity, was rescued by 2-day co-administration of the selective 5-HT2B receptor antagonist LY266097. In the mPFC, 14-day escitalopram administration alone had no effect on pyramidal neuron firing and burst activity, whereas, aripiprazole administered alone or in combination with escitalopram for 14 days increased pyramidal neuron firing and burst activity. Likewise, the administration of LY266097 alone or its addition on the last 3 days of a 14-day escitalopram regimen increased pyramidal neuron firing and burst activity. These results indicated that 5-HT2B receptors play, at least in part, a role in this enhancement. In the hippocampus, 5-HT2B receptor activation by BW723c86 decreased escitalopram-induced inhibition of 5-HT reuptake, which was reversed by a 5-HT2B receptor antagonist. Altogether, these results put into evidence the possibility that 5-HT2B receptor blockade contributes to the therapeutic effect of aripiprazole addition to SSRIs in depression.
Subscribe to Journal
Get full journal access for 1 year
only $43.69 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N. Engl J Med. 2006;354:1243–52.
Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol 2015;25:2318–25.
Luan S, Wan H, Zhang L, Zhao H. Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2018;14:467–77.
Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacol (Berl). 2009;206:335–44.
Haj-Dahmane S. D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci. 2001;14:125–34.
Aman TK, Shen RY, Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharm Exp Ther. 2007;320:376–85.
Ebrahimzadeh M, El Mansari M, Blier P. Synergistic effect of aripiprazole and escitalopram in increasing serotonin but not norepinephrine neurotransmission in the rat hippocampus. Neuropharmacology 2019;146:12–18.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400–11.
Shahid M, Walker GB, Zorn SH, Wong EHF. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23:65–73.
Devroye C, Cathala A, Piazza PV, Spampinato U. The central serotonin 2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: rationale and current status of research. Pharm Ther. 2018;181:143–55.
Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, et al. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res. 2002;943:38–47.
Cathala A, Devroye C, Drutel G, Revest JM, Artigas F, Spampinato U. Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons. Exp Neurol. 2019;311:57–66.
Doly S, Quentin E, Eddine R, Tolu S, Fernandez SP, Bertran-Gonzalez J, et al. Serotonin 2B receptors in mesoaccumbens dopamine pathway regulate cocaine responses. J Neurosci. 2017;37:1354–17.
Duxon MS, Flanigan TP, Reavley TAC, Baxter TGS, Blackburn TP, Fone KCF. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Lett Neurosci. 1997;76:323–9.
Niebert M, Vogelgesang S, Koch UR, Bischoff AM, Kron M, Bock N, et al. Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS ONE 2011;6:e21395.
Diaz SL, Maroteaux L. Implication of 5-HT2B receptors in the serotonin syndrome. Neuropharmacology 2011;61:495–502.
Diaz SL, Doly S, Narboux-Neme N, Fernández S, Mazot P, Banas SM, et al. 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry 2012;17:154–63.
Diaz SL, Narboux-Nême N, Boutourlinsky K, Doly S, Maroteaux L. Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants. Eur Neuropsychopharmacol. 2016;26:265–79.
Belmer A, Quentin E, Diaz SL, Guiard BP, Fernandez SP, Doly S, et al. Positive regulation of raphe serotonin neurons by serotonin 2B receptors. Neuropsychopharmacology 2018;43:1–10.
Launay J-M, Schneider B, Lorie S, Da Prada M, Kellermann O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J. 2006;20:1843–54.
Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP. Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety. Br J Pharm. 1996;117:1443–8.
Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharm. 1999;127:1075–82.
Devroye C, Cathala A, Haddjeri N, Rovera R, Vallée M, Drago F, et al. Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: new opportunities for the treatment of schizophrenia. Neuropharmacology 2016;109:59–68.
Banas SM, Doly S, Boutourlinsky K, Diaz SL, Belmer A, Callebert J, et al. Deconstructing antiobesity compound action: Requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology 2011;36:423–33.
Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology 2012;62:765–74.
Audia JE, Evrard DA, Murdoch GR, Droste JJ, Nissen JS, Schenck KW, et al. Potent, selective tetrahydro-β-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus. J Med Chem. 1996;39:2773–80.
El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an In Vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005;30:1269–77.
Chenu F, Shim S, El Mansari M, Blier P. Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons. J Psychopharmacol. 2014;28:162–7.
Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th edn. Radarweg, AM: Academic Press; 2007.
Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identif Charact Neurosci. 1983;10:301–15.
Ungless MA, Grace AA. Are you or aren’t you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci. 2012;35:422–30.
Vandermaelen CP, Aghajanian GK. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 1983;289:109–19.
Hajós M, Allers KA, Jennings K, Sharp T, Charette G, Sík A, et al. Neurochemical identification of stereotypic burst-firing neurons in the rat dorsal raphe nucleus using juxtacellular labelling methods. Eur J Neurosci. 2007;25:119–26.
Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004;14:1100–9.
Santana N, Mengod G, Artigas F. Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2009;19:849–60.
Riga MS, Teruel-Martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148–55.
Laviolette SR, Lipski WJ, Grace AA. A subpopulation of neurons in the medial prefrontal cortex encodes emotional learning with burst and frequency codes through a dopamine d4 receptor-dependent basolateral amygdala input. J Neurosci. 2005;25:6066–75.
Stumm RK, Zhou C, Schulz S, Höllt V. Neuronal Types Expressing μ- and δ-Opioid Receptor mRNA in the Rat Hippocampal Formation. J Comp Neurol. 2004;469:107–18.
Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006;51:455–66.
Ranck JB. Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. Boston, MA: The Hippocampus. Springer; 1975.
de Montigny C, Wang RY, Reader TA, Aghajanian GK. Monoaminergic denervation of the rat hippocampus: Microiontophoretic studies on pre- and postsynaptic supersensitivity to norepinephrine and serotonin. Brain Res. 1980;200:363–76.
Piñeyro G, Blier P, Dennis T, De Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci. 1994;14:3036–47.
Oosterhof NN, Oosterhof CA. BurstiDAtor: A lightweight discharge analysis program for neural extracellular single unit recordings. Github. https://github.com/nno/burstiDAtor. 2013.
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 2000;865:85–90.
Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas J-P, et al. Serotonin-2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000;36:205–21.
Kennett GA, Trail B, Bright F. Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology 1998;37:1603–10.
Arborelius L, Chergui K, Murase S, Nomikos GG, Hk BB, Chouvet G, et al. The 5-HTIA receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharm. 1993;347:353–62.
Dremencov E, El Mansari M, Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci. 2009;34:223–9.
Devroye C, Haddjeri N, Cathala A, Rovera R, Drago F, Piazza PV, et al. Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2Breceptor blockade: Involvement of medial prefrontal cortex serotonin1Areceptors. Neuropharmacology 2017;119:91–99.
Davidson C, Stamford JA. Evidence that 5‐hydroxytryptamine release in rat dorsal raphé nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors. Br J Pharm. 1995;114:1107–9.
Boothman LJ, Allers KA, Rasmussen K, Sharp T. Evidence that central 5-HT 2A and 5-HT 2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharm. 2003;139:998–1004.
Brouard JT, Schweimer JV, Houlton R, Burnham KE, Quérée P, Sharp T. Pharmacological Evidence for 5-HT6 Receptor Modulation of 5-HT Neuron Firing in Vivo. ACS Chem Neurosci. 2015;6:1241–7.
Mnie-Filali O, Faure C, Lambás-Sẽas L, El Mansari M, Belblidia H, Gondard E, et al. Pharmacological blockade of 5-HT 7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275–88.
Zhang YW, Rudnick G. Serotonin transporter mutations associated with obsessive-compulsive disorder and phosphorylation alter binding affinity for inhibitors. Neuropharmacology 2005;49:791–7.
Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharm. 2004;493:75–83.
Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, et al. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: Influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch Pharm. 2002;365:242–52.
Bergqvist PBF, Dong J, Blier P. Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study. Psychopharmacol (Berl). 1999;143:89–96.
Wainscott B, Nelson L, Lilly E. Pharmacologic characterization of the human 5-HT2B receptor: evidence for species differences. J Pharm Exp Ther. 1996;276:720–7.
Gronier BS, Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Lett. 2003;349:196–200.
Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252–65.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hamati, R., El Mansari, M. & Blier, P. Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. Neuropsychopharmacol. (2020). https://doi.org/10.1038/s41386-020-0723-y